Pablo Legorreta is Chairman and Chief Executive Officer of Royalty Pharma plc (RPRX). The company reported total compensation of $937,500 for fiscal year 2025.
| Salary | $937,500 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $0 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $937,500 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Royalty Pharma plc filed April 10, 2026, accession 0001140361-26-014239.
| Peer-group chief executive median | $26,139,211 |
|---|---|
| Difference from that median | $-25,201,710 |
| Percentile within the disclosed peer group | 6th |
| Peers with a disclosed figure | 18 |
Medians and percentiles are computed across the peer group Royalty Pharma plc discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Marshall Urist | Executive Vice President, Research & Investments | $1,323,000 |
| George Lloyd | Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | $1,323,000 |
| Christopher Hite | Executive Vice President & Vice Chairman | $1,323,000 |
| Terrance Coyne | Executive Vice President & Chief Financial Officer | $1,323,000 |
| Pablo Legorreta this page | Chairman and Chief Executive Officer | $937,500 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Royalty Pharma plc compensation brief.
Pablo Legorreta's compensation sits inside Royalty Pharma plc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.